Literature DB >> 7644246

Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron.

Harald Schwörer1, Heinz Hartmann, Giuliano Ramadori.   

Abstract

The objective of the present study was to determine whether ondansetron, a specific serotonin type 3 receptor antagonist (5-HT3), relieves cholestatic pruritus in patients resistant to conventional antipruritic therapy (antihistamines and cholestyramine). In a placebo-controlled study the acute effect of an intravenous injection of ondansetron (4 mg, 8 mg) or placebo (NaCl solution) was tested in 10 patients (41-66 years of age; 4 men, 6 women) with cholestatic itch. A successful treatment was assessed when the intensity of itch was reduced by 50% or more within 2 h after injection of ondansetron. Intensity of itch was determined by the patients on a visual rating scale from 0 to 10. Ondansetron reduced or abolished pruritus within 30-60 min after injection. A 50% reduction of the intensity of itch was observed up to 6 h after injection of 8 mg. The effect was reproducible in the same patient. In conclusion ondansetron is effective in the treatment of cholestatic itch. Serotonin may participate in the generation and/or sensation of cholestatic pruritus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644246     DOI: 10.1016/0304-3959(94)00145-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  34 in total

Review 1.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!

Authors:  N M Barnes
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

4.  Why do cholestatic patients itch?

Authors:  E A Jones; N V Bergasa
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

5.  Ondansetron for pruritus in child with chronic cholestasis.

Authors:  P Trioche; D Samuel; M Odièvre; P Labrune
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

6.  Four Possible Itching Pathways Related to the TRPV1 Channel, Histamine, PAR-2 and Serotonin.

Authors:  Hiroshi Nakagawa; Akio Hiura
Journal:  Malays J Med Sci       Date:  2013-07

7.  Ondansetron for paediatric uraemic pruritus: a case report.

Authors:  Pankaj V Deshpande
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

Review 8.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 9.  The Return of the Mast Cell: New Roles in Neuroimmune Itch Biology.

Authors:  Fang Wang; Ting-Lin B Yang; Brian S Kim
Journal:  J Invest Dermatol       Date:  2020-04-02       Impact factor: 8.551

Review 10.  Treatment of pruritus associated with systemic disorders in the elderly: a review of the role of new therapies.

Authors:  Ann Lonsdale-Eccles; Andrew J Carmichael
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.